A Phase 1b/2a Study of KINE-101 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Latest Information Update: 17 Sep 2024
Price :
$35 *
At a glance
- Drugs KINE 101 A (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Adverse reactions
- 17 Sep 2024 New trial record
- 13 Sep 2024 According to Kine Sciences media release, first patient was dosed in this trial.